{
  "id": "mycobacterium-avium-complex",
  "title": "Mycobacterium avium complex",
  "lang": "en",
  "source_lang": "en",
  "summary": "Mycobacterium avium complex is a group of closely related environmental bacteria that can cause pulmonary, lymph-node, and disseminated infections, especially in susceptible hosts.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "MAC",
    "M. avium complex"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/mycobacterium-avium-complex/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/mycobacterium-avium-complex/",
      "json": "https://aiwiki.page/zh/mycobacterium-avium-complex.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Mycobacterium avium complex (MAC) is a group of closely related, slow-growing bacteria within the genus Mycobacterium. Its best-known members are Mycobacterium avium and Mycobacterium intracellulare. These organisms occur widely in water, soil, and dust. They belong to the nontuberculous mycobacteria, a category distinct from the organisms responsible for tuberculosis and leprosy. Exposure is common, but disease occurs mainly in people with particular vulnerabilities, including structural lung disease or impaired cellular immunity. Isolation of MAC from a specimen does not, by itself, establish infection requiring treatment."
    },
    {
      "heading": "Classification and biological characteristics",
      "text": "MAC is a species complex rather than a single bacterial species. Historically, laboratories often identified its members collectively because conventional biochemical methods could not reliably distinguish them. Molecular methods have revealed additional members, including M. chimaera, and have refined relationships within the group. The precise composition of the complex depends partly on the taxonomic framework used.\n\nLike other mycobacteria, MAC organisms have a lipid-rich cell wall containing mycolic acids. This structure contributes to their characteristic acid-fast staining: stained organisms retain certain dyes despite treatment with acid-alcohol. Acid-fast staining cannot, however, distinguish MAC from other mycobacteria.\n\nMAC organisms grow relatively slowly in laboratory culture, with detection and identification commonly taking weeks. They can survive within macrophages, immune cells that normally engulf and destroy microorganisms. Their capacity for intracellular persistence is important in disease development."
    },
    {
      "heading": "Environmental reservoirs and acquisition",
      "text": "MAC organisms inhabit natural and engineered water systems, soil, and dust. They can form biofilms on surfaces, including those in plumbing systems. Their environmental persistence helps explain why exposure is widespread and why respiratory specimens can occasionally contain MAC without evidence of disease.\n\nAcquisition is generally attributed to environmental exposure, including inhalation of contaminated aerosols or entry through the gastrointestinal tract. Ordinary person-to-person spread is not considered a usual route of MAC transmission, unlike pulmonary tuberculosis.\n\nA distinct healthcare-associated example involves M. chimaera. Contaminated heater-cooler devices used during cardiac surgery have been linked to invasive infections following exposure to aerosols generated by the devices. These outbreaks illustrate an equipment-associated exposure pathway rather than ordinary interpersonal transmission."
    },
    {
      "heading": "Major forms of disease",
      "text": "Pulmonary disease\n\nChronic lung disease is a major clinical manifestation of MAC infection. Symptoms may include persistent cough, sputum production, fatigue, weight loss, and coughing up blood. These findings are not specific to MAC.\n\nTwo commonly recognized patterns are:\n\n- Nodular-bronchiectatic disease, characterized by small lung nodules and bronchiectasis, or permanent widening of airways.\n- Fibrocavitary disease, characterized by cavities and scarring, often involving the upper lungs and occurring in people with underlying lung damage.\n\nThese patterns can overlap. Chronic obstructive pulmonary disease, bronchiectasis, and other structural lung abnormalities are associated with increased susceptibility. Some affected individuals have no previously recognized immune deficiency.\n\nLymph-node disease\n\nMAC can cause localized inflammation of lymph nodes, especially cervical lymphadenitis in young children. It often presents as gradually enlarging lymph nodes on one side of the neck, sometimes with discoloration of the overlying skin. This localized presentation differs from disseminated infection in severely immunocompromised people.\n\nDisseminated disease\n\nDisseminated MAC involves spread beyond a single local site and can affect the blood, lymph nodes, liver, spleen, bone marrow, and other organs. It is particularly associated with advanced HIV infection and profound depletion of CD4 T cells, although other forms of immune suppression can also predispose to it.\n\nManifestations include fever, night sweats, weight loss, diarrhea, abdominal discomfort, and anemia. Effective antiretroviral therapy substantially reduced the occurrence of disseminated MAC among people with HIV.\n\nLess common localized infections involve skin, soft tissue, bone, or joints."
    },
    {
      "heading": "Host response and susceptibility",
      "text": "Control of MAC depends heavily on cell-mediated immunity. Macrophages interact with T cells and signaling molecules such as interferon-gamma to restrict intracellular bacterial growth. Defects affecting these defenses can increase susceptibility to extensive or recurrent mycobacterial disease.\n\nIn pulmonary infection, impaired airway clearance and structural damage can permit organisms to persist. Infection and inflammation may then contribute to further airway injury. Disease development therefore reflects both microbial characteristics and host factors; exposure alone does not explain who becomes ill."
    },
    {
      "heading": "Diagnosis",
      "text": "Pulmonary MAC diagnosis requires integration of symptoms, imaging, and microbiological evidence. A positive sputum culture alone may reflect transient presence or specimen contamination rather than active disease.\n\nEstablished diagnostic criteria generally require compatible clinical and radiological findings, exclusion of alternative explanations, and supporting microbiology. Microbiological evidence may include repeated sputum cultures yielding the same species, a positive bronchoscopic specimen, or compatible biopsy findings with culture evidence.\n\nCulture remains important for recovering organisms and assessing drug susceptibility. Molecular identification methods, including DNA sequencing, can distinguish species that conventional laboratory tests cannot reliably separate. Species identification also helps differentiate MAC from M. tuberculosis and other nontuberculous mycobacteria.\n\nFor disseminated disease, blood cultures and cultures or examination of involved tissues can provide diagnostic evidence."
    },
    {
      "heading": "Treatment and clinical course",
      "text": "MAC disease is treated with combinations of antimicrobial drugs rather than a single agent. For macrolide-susceptible pulmonary MAC, commonly used regimens include a macrolide, ethambutol, and a rifamycin. Additional agents, including aminoglycosides, are used in selected circumstances. Treatment is prolonged, and its composition depends on disease site, severity, susceptibility results, and host factors.\n\nAntimicrobial resistance, particularly macrolide resistance, can substantially limit treatment effectiveness. Drug toxicity, interactions, and the organisms’ persistence also complicate management. In disseminated HIV-associated disease, restoration of immune function through antiretroviral therapy is an important component of disease control.\n\nPulmonary MAC has a variable course: some cases remain relatively stable, whereas others progress. Recurrence after treatment can represent either relapse with the original strain or reinfection from an environmental source. Consequently, microbiological clearance does not confer lasting protection against a later episode."
    }
  ],
  "links": [
    "bacteria",
    "species",
    "cell-wall",
    "macrophage",
    "biofilm",
    "hiv-aids",
    "t-cell",
    "immune-system",
    "interferon",
    "inflammation",
    "diagnosis",
    "dna-sequencing",
    "antimicrobial-resistance"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}